There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

CAMBRIDGE, Mass., November 04, 2024--2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held ...

Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received an average rating of “Moderate Buy” from the nine ...

Exchange Traded Concepts LLC lowered its holdings in 2seventy bio, Inc. (NASDAQ:TSVT – Free Report) by 36.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 34,816 shares of the ...

TD Cowen analyst Yaron Werber maintained a Hold rating on 2seventy bio (TSVT – Research Report) today. The company’s shares closed ...

On September 25, 2024, 2seventy bio issued a press release announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel ...

European Commission decision expected in two months. Vandana Singh Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability ...

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, ...

Short interest in 2seventy bio Inc (NASDAQ:TSVT) increased during the last reporting period, rising from 5.13M to 5.32M. This put 12.5% of the company's publicly available shares short.

CAMBRIDGE, Mass. - 2seventy bio, Inc. (NASDAQ:TSVT) and Bristol Myers Squibb (NYSE:BMY) have jointly announced the discontinuation of enrollment in the Phase 3 KarMMa-9 study. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...